11
Participants
Start Date
November 1, 2020
Primary Completion Date
October 31, 2021
Study Completion Date
December 31, 2021
Cobicistat
Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
Maastricht University Medical Centre, Maastricht
Antoni van Leeuwenhoek hospital, Amsterdam
The Netherlands Cancer Institute
OTHER
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Academisch Ziekenhuis Maastricht
OTHER